Navigation Links
Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Date:4/4/2008

e separation of stem cell populations for BTI's cell therapy work."

About Bioprocessing Technology Institute (BTI)

Bioprocessing Technology Institute (BTI) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 1990 as the Bioprocessing Technology Unit, it was renamed the Bioprocessing Technology Institute (BTI) in 2003. The research institute's mission is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocessing community. Some of the key research areas include expression engineering, animal cell technology, stem cell research, microbial fermentation, downstream purification and analytics. More information on BTI can be found at http://www.bti.a-star.edu.sg.

About Raven biotechnologies

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.; Bioprocessing TechnologyInstitute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
3. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
4. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
5. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
11. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/26/2015)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... for the detection of foodborne pathogens, today reported ... full year ended December 31, 2014. ... ended December 31, 2014 was $1.4 million compared ... and $1.5 million for the third quarter of ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... Bulletin Board: DSCI), a provider of advanced wound care ... based on a,number of new products that are finding ... direct salespersons in the US a year ago, now,has ... increase is a significant one,for Derma Sciences, which has ...
... pre-adoption clinical evaluation of ... Recent case of vCJD now means that all the population is susceptible to ... the disease, - Increased concerns over "second wave" of vCJD in individuals with much ... longer incubation times - P-Capt(R) prion reduction filter still the only proven method ...
... 17, 2008 Scientific studies on climate change, energy ... more than 145 million processing hours on supercomputers at ... Innovative and Novel Computational Impact on Theory and Experiment ... industry, academia and government research facilities receive access to ...
Cached Biology Technology:Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 2Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 2ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 4ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 5Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... allow women diagnosed with cancer the opportunity to have children ... researchers at the University of Michigan Comprehensive Cancer Center have ... cancer treatments, a woman can preserve the hope of one ... thawing them safely so they can lead to pregnancy is ...
... cause of death among children in developing regions of ... or international health organizations and charities, according to investigators ... of pediatric cancer is occurring as the number of ... the efforts of the World Health Organization and international ...
... critical inhibitory step that is a key component ... neutrophil production and destruction. The research, published in ... process for disposal of dying neutrophils is actively ... the processes that control neutrophil turnover may contribute ...
Cached Biology News:Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 2Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 3Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: